Fulgent Genetics Inc
For the period ended Mar 31, 2024. Filed May 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 3, 2024
FLGT$25.78-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flow from operating activities: | ||
| Net loss from consolidated operations | $(13,846) | $(15,849) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Equity-based compensation | 11,518 | 10,265 |
| Depreciation and amortization | 6,663 | 6,879 |
| Gain for credit losses | (2,497) | (113) |
| Noncash lease expense | 1,510 | 1,561 |
| Loss (gain) on disposal of fixed asset | 183 | (179) |
| Amortization of discount of marketable securities | (1,184) | (478) |
| Deferred taxes | (557) | (5,200) |
| Net realized loss on marketable securities | 580 | — |
| Other | (12) | — |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | 1,484 | 9,331 |
| Other current and long-term assets | 5,130 | (1,629) |
| Accounts payable | (245) | (1,855) |
| Accrued liabilities and other liabilities | 51 | (9,114) |
| Operating and finance lease liabilities | (1,512) | (1,526) |
| Net cash provided by (used in) operating activities | 7,266 | (7,907) |
| Cash flow from investing activities: | ||
| Purchase of marketable securities | (195,741) | (143,926) |
| Purchases of fixed assets | (4,056) | (2,034) |
| Proceeds from sale of fixed assets | 258 | 198 |
| Maturities of marketable securities | 95,450 | 141,408 |
| Proceeds from sale of marketable securities | 56,903 | — |
| Net cash used in investing activities | (47,186) | (4,354) |
| Cash flow from financing activities: | ||
| Common stock withholding for employee tax obligations | (1,682) | (869) |
| Repayment of notes payable | (765) | — |
| Repurchase of common stock | (225) | — |
| Principal paid for finance lease | (135) | (232) |
| Net cash used in financing activities | (2,807) | (1,101) |
| Effect of exchange rate changes on cash and cash equivalents | (69) | 28 |
| Net decrease in cash and cash equivalents | (42,796) | (13,334) |
| Cash and cash equivalents at beginning of period | 97,473 | 79,506 |
| Cash and cash equivalents at end of period | $54,677 | $66,172 |
| Supplemental disclosures of cash flow information: | ||
| Income taxes paid | $1,307 | $1,680 |
| Cash paid for interest | $439 | $— |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Purchases of marketable securities in other current liabilities | $— | $3,519 |
| Purchases of fixed assets in accounts payable | $4,739 | $2,537 |
| Sale of fixed assets in other receivable | $11 | $— |
| Operating lease right-of-use assets reduced due to lease termination | $57 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.